Cite
Combined inhibition of MET and VEGF enhances therapeutic efficacy of EGFR TKIs in EGFR-mutant non-small cell lung cancer with concomitant aberrant MET activation.
MLA
Huang, Shanshan, et al. “Combined Inhibition of MET and VEGF Enhances Therapeutic Efficacy of EGFR TKIs in EGFR-Mutant Non-Small Cell Lung Cancer with Concomitant Aberrant MET Activation.” Experimental Hematology & Oncology, vol. 13, no. 1, Oct. 2024, pp. 1–14. EBSCOhost, https://doi.org/10.1186/s40164-024-00565-9.
APA
Huang, S., Long, Y., Gao, Y., Lin, W., Wang, L., Jiang, J., Yuan, X., Chen, Y., Zhang, P., & Chu, Q. (2024). Combined inhibition of MET and VEGF enhances therapeutic efficacy of EGFR TKIs in EGFR-mutant non-small cell lung cancer with concomitant aberrant MET activation. Experimental Hematology & Oncology, 13(1), 1–14. https://doi.org/10.1186/s40164-024-00565-9
Chicago
Huang, Shanshan, Yaling Long, Yuan Gao, Wanling Lin, Lei Wang, Jizong Jiang, Xun Yuan, Yuan Chen, Peng Zhang, and Qian Chu. 2024. “Combined Inhibition of MET and VEGF Enhances Therapeutic Efficacy of EGFR TKIs in EGFR-Mutant Non-Small Cell Lung Cancer with Concomitant Aberrant MET Activation.” Experimental Hematology & Oncology 13 (1): 1–14. doi:10.1186/s40164-024-00565-9.